Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models
Recent investigations suggested that anticancer agents may inhibit the progression of Alzheimer's disease (AD) pathology. Conyza dioscoridis (L.) was demonstrated to have anticancer, antioxidant, anti-inflammatory and antidiabetic effects. This study was carried out to investigate the efficacy...
Gespeichert in:
| Veröffentlicht in: | BMC complementary and alternative medicine 2022-11, Vol.22 (1), p.288 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 288 |
| container_title | BMC complementary and alternative medicine |
| container_volume | 22 |
| creator | Gomaa, Adel A Farghaly, Hanan S M Makboul, Rania M Hussien, Abeer M Nicola, Mariam A |
| description | Recent investigations suggested that anticancer agents may inhibit the progression of Alzheimer's disease (AD) pathology. Conyza dioscoridis (L.) was demonstrated to have anticancer, antioxidant, anti-inflammatory and antidiabetic effects. This study was carried out to investigate the efficacy of polyphenols from Conyza dioscoridis (L.) extract (PCDE) on AD.
Impacts of 3 doses of PCDE and donepezil, a reference drug, on the features of Alzheimer's disease in two animal models were investigated.
PCDE ameliorated the memory and learning impairment shown in rats following a single dose of scopolamine (scopolamine model) or 17 weeks of high-fat/high-fructose(HF/Hfr) diet coupled with a single dose of streptozotocin, (25 mg/kg) (T2D model). They reduced significantly the high hippocampal cholinesterase activity in the two models of rats. Administration of PCDE for 8 weeks in the T2D model showed a significant reduction in hippocampal GSK-3β, caspase-3 activity and increase in the inhibited glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B). A significant reduction of HOMA-insulin resistance and serum hypercholesterolemia was observed. The Tau hyperphosphorylation and Aβ 1-42 generation in the hippocampal of T2D rats were significantly decreased by PCDE. Modulation of the oxidative stress markers, (rise in GH and SOD; decrease in MDA levels) and a significant reduction of TNF-α and IL-1β in the hippocampus of T2D rats treated by PCDE extract were important findings in this study. The highest dose tested was 4% of the highest safe dose.
Our study suggests that PCDE is multi-targeting agent with multiple beneficial activities in combating features of AD. This study may provide a novel therapeutic strategy for AD treatment that warrants clinical studies. |
| doi_str_mv | 10.1186/s12906-022-03765-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9644610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A725831048</galeid><sourcerecordid>A725831048</sourcerecordid><originalsourceid>FETCH-LOGICAL-g392t-9ee40f3fc3c7054b84e2019849429633fc1dc08a55071405013fa15bf59bce613</originalsourceid><addsrcrecordid>eNptktuKFDEQhhtR3GXcF_BCAoKHix5z6E53boRh8AQDeqHXTSZd3V1rOhmT9MrsW_jGBl2XGZBcJFR99VP1V4riKaNrxlr5JjKuqCwp5yUVjaxL-qC45FLyspENe3jyviiuYrymlHLBRCPqx8WFkKJqBVeXxa8v3h4PEzhvIxmCn8nWu-OtJj36aHzAHiN5tVu_JnoGiz7oBGRjbyfAGcLLmLkIOkJJLH4Hom2CjKB3kaQp-GWcyLzYhGXSYYSEbiTaJLzBhBAJOpJ-eqIdztqS2fdg45Pi0aBthKu7e1V8e__u6_Zjufv84dN2sytHoXgqFUBFBzEYYRpaV_u2Ak6ZaitVcSVFTrDe0FbXNW1YRWvKxKBZvR9qtTcgmVgVb__qHpb9DL0Bl4K23SHkXsKx8xq784zDqRv9TadkVUlGs8DzO4HgfywQU3ftl-Byzx1v8kqkarPP99SoLXToBp_FzIzRdJuG161gNK9iVaz_Q-XTw4zGOxgwx88KXpwUTJCNn6K3yx_rz8Fnp2Pez_fvC4jfK7G1Cg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2737669836</pqid></control><display><type>article</type><title>Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models</title><source>SpringerOpen</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Gomaa, Adel A ; Farghaly, Hanan S M ; Makboul, Rania M ; Hussien, Abeer M ; Nicola, Mariam A</creator><creatorcontrib>Gomaa, Adel A ; Farghaly, Hanan S M ; Makboul, Rania M ; Hussien, Abeer M ; Nicola, Mariam A</creatorcontrib><description>Recent investigations suggested that anticancer agents may inhibit the progression of Alzheimer's disease (AD) pathology. Conyza dioscoridis (L.) was demonstrated to have anticancer, antioxidant, anti-inflammatory and antidiabetic effects. This study was carried out to investigate the efficacy of polyphenols from Conyza dioscoridis (L.) extract (PCDE) on AD.
Impacts of 3 doses of PCDE and donepezil, a reference drug, on the features of Alzheimer's disease in two animal models were investigated.
PCDE ameliorated the memory and learning impairment shown in rats following a single dose of scopolamine (scopolamine model) or 17 weeks of high-fat/high-fructose(HF/Hfr) diet coupled with a single dose of streptozotocin, (25 mg/kg) (T2D model). They reduced significantly the high hippocampal cholinesterase activity in the two models of rats. Administration of PCDE for 8 weeks in the T2D model showed a significant reduction in hippocampal GSK-3β, caspase-3 activity and increase in the inhibited glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B). A significant reduction of HOMA-insulin resistance and serum hypercholesterolemia was observed. The Tau hyperphosphorylation and Aβ 1-42 generation in the hippocampal of T2D rats were significantly decreased by PCDE. Modulation of the oxidative stress markers, (rise in GH and SOD; decrease in MDA levels) and a significant reduction of TNF-α and IL-1β in the hippocampus of T2D rats treated by PCDE extract were important findings in this study. The highest dose tested was 4% of the highest safe dose.
Our study suggests that PCDE is multi-targeting agent with multiple beneficial activities in combating features of AD. This study may provide a novel therapeutic strategy for AD treatment that warrants clinical studies.</description><identifier>ISSN: 2662-7671</identifier><identifier>EISSN: 2662-7671</identifier><identifier>EISSN: 1472-6882</identifier><identifier>DOI: 10.1186/s12906-022-03765-0</identifier><identifier>PMID: 36348329</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Advertising executives ; Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Analysis ; Animal diseases ; Animal models ; Animals ; Anticancer properties ; Antidiabetics ; Antioxidants ; Antitumor agents ; Asteraceae ; Cancer ; Care and treatment ; Caspase-3 ; Cholinesterase ; Conyza ; Dementia ; Diabetes mellitus ; Diabetes Mellitus, Type 2 ; Donepezil ; Fructose ; Glutamate ; Glutamate receptors ; Glutamic acid receptors (ionotropic) ; Glycogen Synthase Kinase 3 beta ; High fat diet ; Hippocampus ; Hypercholesterolemia ; IL-1β ; Inflammation ; Insulin ; Insulin resistance ; Medical research ; Medicine, Experimental ; Models, Animal ; N-Methyl-D-aspartic acid receptors ; Neurodegenerative diseases ; Oxidative stress ; Phosphorylation ; Polyphenols ; Polyphenols - pharmacology ; Rats ; Rats, Wistar ; Receptors ; Reduction ; Rodents ; Scopolamine ; Scopolamine - therapeutic use ; Streptozocin ; Tau protein ; Tumor necrosis factor-α ; Type 2 diabetes ; α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid</subject><ispartof>BMC complementary and alternative medicine, 2022-11, Vol.22 (1), p.288</ispartof><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644610/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644610/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36348329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gomaa, Adel A</creatorcontrib><creatorcontrib>Farghaly, Hanan S M</creatorcontrib><creatorcontrib>Makboul, Rania M</creatorcontrib><creatorcontrib>Hussien, Abeer M</creatorcontrib><creatorcontrib>Nicola, Mariam A</creatorcontrib><title>Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models</title><title>BMC complementary and alternative medicine</title><addtitle>BMC Complement Med Ther</addtitle><description>Recent investigations suggested that anticancer agents may inhibit the progression of Alzheimer's disease (AD) pathology. Conyza dioscoridis (L.) was demonstrated to have anticancer, antioxidant, anti-inflammatory and antidiabetic effects. This study was carried out to investigate the efficacy of polyphenols from Conyza dioscoridis (L.) extract (PCDE) on AD.
Impacts of 3 doses of PCDE and donepezil, a reference drug, on the features of Alzheimer's disease in two animal models were investigated.
PCDE ameliorated the memory and learning impairment shown in rats following a single dose of scopolamine (scopolamine model) or 17 weeks of high-fat/high-fructose(HF/Hfr) diet coupled with a single dose of streptozotocin, (25 mg/kg) (T2D model). They reduced significantly the high hippocampal cholinesterase activity in the two models of rats. Administration of PCDE for 8 weeks in the T2D model showed a significant reduction in hippocampal GSK-3β, caspase-3 activity and increase in the inhibited glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B). A significant reduction of HOMA-insulin resistance and serum hypercholesterolemia was observed. The Tau hyperphosphorylation and Aβ 1-42 generation in the hippocampal of T2D rats were significantly decreased by PCDE. Modulation of the oxidative stress markers, (rise in GH and SOD; decrease in MDA levels) and a significant reduction of TNF-α and IL-1β in the hippocampus of T2D rats treated by PCDE extract were important findings in this study. The highest dose tested was 4% of the highest safe dose.
Our study suggests that PCDE is multi-targeting agent with multiple beneficial activities in combating features of AD. This study may provide a novel therapeutic strategy for AD treatment that warrants clinical studies.</description><subject>Advertising executives</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Analysis</subject><subject>Animal diseases</subject><subject>Animal models</subject><subject>Animals</subject><subject>Anticancer properties</subject><subject>Antidiabetics</subject><subject>Antioxidants</subject><subject>Antitumor agents</subject><subject>Asteraceae</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Caspase-3</subject><subject>Cholinesterase</subject><subject>Conyza</subject><subject>Dementia</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Donepezil</subject><subject>Fructose</subject><subject>Glutamate</subject><subject>Glutamate receptors</subject><subject>Glutamic acid receptors (ionotropic)</subject><subject>Glycogen Synthase Kinase 3 beta</subject><subject>High fat diet</subject><subject>Hippocampus</subject><subject>Hypercholesterolemia</subject><subject>IL-1β</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Models, Animal</subject><subject>N-Methyl-D-aspartic acid receptors</subject><subject>Neurodegenerative diseases</subject><subject>Oxidative stress</subject><subject>Phosphorylation</subject><subject>Polyphenols</subject><subject>Polyphenols - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors</subject><subject>Reduction</subject><subject>Rodents</subject><subject>Scopolamine</subject><subject>Scopolamine - therapeutic use</subject><subject>Streptozocin</subject><subject>Tau protein</subject><subject>Tumor necrosis factor-α</subject><subject>Type 2 diabetes</subject><subject>α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid</subject><issn>2662-7671</issn><issn>2662-7671</issn><issn>1472-6882</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptktuKFDEQhhtR3GXcF_BCAoKHix5z6E53boRh8AQDeqHXTSZd3V1rOhmT9MrsW_jGBl2XGZBcJFR99VP1V4riKaNrxlr5JjKuqCwp5yUVjaxL-qC45FLyspENe3jyviiuYrymlHLBRCPqx8WFkKJqBVeXxa8v3h4PEzhvIxmCn8nWu-OtJj36aHzAHiN5tVu_JnoGiz7oBGRjbyfAGcLLmLkIOkJJLH4Hom2CjKB3kaQp-GWcyLzYhGXSYYSEbiTaJLzBhBAJOpJ-eqIdztqS2fdg45Pi0aBthKu7e1V8e__u6_Zjufv84dN2sytHoXgqFUBFBzEYYRpaV_u2Ak6ZaitVcSVFTrDe0FbXNW1YRWvKxKBZvR9qtTcgmVgVb__qHpb9DL0Bl4K23SHkXsKx8xq784zDqRv9TadkVUlGs8DzO4HgfywQU3ftl-Byzx1v8kqkarPP99SoLXToBp_FzIzRdJuG161gNK9iVaz_Q-XTw4zGOxgwx88KXpwUTJCNn6K3yx_rz8Fnp2Pez_fvC4jfK7G1Cg</recordid><startdate>20221108</startdate><enddate>20221108</enddate><creator>Gomaa, Adel A</creator><creator>Farghaly, Hanan S M</creator><creator>Makboul, Rania M</creator><creator>Hussien, Abeer M</creator><creator>Nicola, Mariam A</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20221108</creationdate><title>Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models</title><author>Gomaa, Adel A ; Farghaly, Hanan S M ; Makboul, Rania M ; Hussien, Abeer M ; Nicola, Mariam A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g392t-9ee40f3fc3c7054b84e2019849429633fc1dc08a55071405013fa15bf59bce613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Advertising executives</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Analysis</topic><topic>Animal diseases</topic><topic>Animal models</topic><topic>Animals</topic><topic>Anticancer properties</topic><topic>Antidiabetics</topic><topic>Antioxidants</topic><topic>Antitumor agents</topic><topic>Asteraceae</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Caspase-3</topic><topic>Cholinesterase</topic><topic>Conyza</topic><topic>Dementia</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Donepezil</topic><topic>Fructose</topic><topic>Glutamate</topic><topic>Glutamate receptors</topic><topic>Glutamic acid receptors (ionotropic)</topic><topic>Glycogen Synthase Kinase 3 beta</topic><topic>High fat diet</topic><topic>Hippocampus</topic><topic>Hypercholesterolemia</topic><topic>IL-1β</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Models, Animal</topic><topic>N-Methyl-D-aspartic acid receptors</topic><topic>Neurodegenerative diseases</topic><topic>Oxidative stress</topic><topic>Phosphorylation</topic><topic>Polyphenols</topic><topic>Polyphenols - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors</topic><topic>Reduction</topic><topic>Rodents</topic><topic>Scopolamine</topic><topic>Scopolamine - therapeutic use</topic><topic>Streptozocin</topic><topic>Tau protein</topic><topic>Tumor necrosis factor-α</topic><topic>Type 2 diabetes</topic><topic>α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomaa, Adel A</creatorcontrib><creatorcontrib>Farghaly, Hanan S M</creatorcontrib><creatorcontrib>Makboul, Rania M</creatorcontrib><creatorcontrib>Hussien, Abeer M</creatorcontrib><creatorcontrib>Nicola, Mariam A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomaa, Adel A</au><au>Farghaly, Hanan S M</au><au>Makboul, Rania M</au><au>Hussien, Abeer M</au><au>Nicola, Mariam A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models</atitle><jtitle>BMC complementary and alternative medicine</jtitle><addtitle>BMC Complement Med Ther</addtitle><date>2022-11-08</date><risdate>2022</risdate><volume>22</volume><issue>1</issue><spage>288</spage><pages>288-</pages><issn>2662-7671</issn><eissn>2662-7671</eissn><eissn>1472-6882</eissn><abstract>Recent investigations suggested that anticancer agents may inhibit the progression of Alzheimer's disease (AD) pathology. Conyza dioscoridis (L.) was demonstrated to have anticancer, antioxidant, anti-inflammatory and antidiabetic effects. This study was carried out to investigate the efficacy of polyphenols from Conyza dioscoridis (L.) extract (PCDE) on AD.
Impacts of 3 doses of PCDE and donepezil, a reference drug, on the features of Alzheimer's disease in two animal models were investigated.
PCDE ameliorated the memory and learning impairment shown in rats following a single dose of scopolamine (scopolamine model) or 17 weeks of high-fat/high-fructose(HF/Hfr) diet coupled with a single dose of streptozotocin, (25 mg/kg) (T2D model). They reduced significantly the high hippocampal cholinesterase activity in the two models of rats. Administration of PCDE for 8 weeks in the T2D model showed a significant reduction in hippocampal GSK-3β, caspase-3 activity and increase in the inhibited glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B). A significant reduction of HOMA-insulin resistance and serum hypercholesterolemia was observed. The Tau hyperphosphorylation and Aβ 1-42 generation in the hippocampal of T2D rats were significantly decreased by PCDE. Modulation of the oxidative stress markers, (rise in GH and SOD; decrease in MDA levels) and a significant reduction of TNF-α and IL-1β in the hippocampus of T2D rats treated by PCDE extract were important findings in this study. The highest dose tested was 4% of the highest safe dose.
Our study suggests that PCDE is multi-targeting agent with multiple beneficial activities in combating features of AD. This study may provide a novel therapeutic strategy for AD treatment that warrants clinical studies.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>36348329</pmid><doi>10.1186/s12906-022-03765-0</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2662-7671 |
| ispartof | BMC complementary and alternative medicine, 2022-11, Vol.22 (1), p.288 |
| issn | 2662-7671 2662-7671 1472-6882 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9644610 |
| source | SpringerOpen; MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink; PubMed Central; PubMed Central Open Access |
| subjects | Advertising executives Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer's disease Analysis Animal diseases Animal models Animals Anticancer properties Antidiabetics Antioxidants Antitumor agents Asteraceae Cancer Care and treatment Caspase-3 Cholinesterase Conyza Dementia Diabetes mellitus Diabetes Mellitus, Type 2 Donepezil Fructose Glutamate Glutamate receptors Glutamic acid receptors (ionotropic) Glycogen Synthase Kinase 3 beta High fat diet Hippocampus Hypercholesterolemia IL-1β Inflammation Insulin Insulin resistance Medical research Medicine, Experimental Models, Animal N-Methyl-D-aspartic acid receptors Neurodegenerative diseases Oxidative stress Phosphorylation Polyphenols Polyphenols - pharmacology Rats Rats, Wistar Receptors Reduction Rodents Scopolamine Scopolamine - therapeutic use Streptozocin Tau protein Tumor necrosis factor-α Type 2 diabetes α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid |
| title | Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer's disease- like alterations through multi-targeting activities in two animal models |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T16%3A38%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyphenols%20from%20Conyza%20dioscoridis%20(L.)%20ameliorate%20Alzheimer's%20disease-%20like%20alterations%20through%20multi-targeting%20activities%20in%20two%20animal%20models&rft.jtitle=BMC%20complementary%20and%20alternative%20medicine&rft.au=Gomaa,%20Adel%20A&rft.date=2022-11-08&rft.volume=22&rft.issue=1&rft.spage=288&rft.pages=288-&rft.issn=2662-7671&rft.eissn=2662-7671&rft_id=info:doi/10.1186/s12906-022-03765-0&rft_dat=%3Cgale_pubme%3EA725831048%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2737669836&rft_id=info:pmid/36348329&rft_galeid=A725831048&rfr_iscdi=true |